Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC study

Pediatrics

Volumn 116, Issue 2, 2005, Pages 360-369

  Garcia, M Luz Garcia ^a   Wahn, Ulrich ^b   Gilles, Leen ^c   Swern, Arlene ^c   Tozzi, Carol A ^c   Polos, Peter ^c  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Asthma control; Inhaled corticosteroid; Randomized controlled trial; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST; SALMETEROL XINAFOATE; XANTHINE; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADOLESCENT; ANALYSIS OF COVARIANCE; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES;

EID: 27944483130     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-1172     Document Type: Article

References (31)

1. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma: United States, 1980-1999. MMWR CDC Surveill Summ. 2002;51:1-13
2. Woolcock AJ, Peat JK. Evidence for the increase in asthma worldwide. In: The Rising Trends in Asthma. Chichester, United Kingdom: John Wiley and Sons; 1997:122-139. Ciba Foundation Symposium 206
3. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 1999;82:233-252
4. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340:197-206
5. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213-1220
6. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children. JAMA. 1998;279:1181-1186
7. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3). Available at: www.pediatrics.org/cgi/ content/full/108/3/e48
8. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health; 1997. NIH Publication 97-4051
9. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health; 1998. NIH Publication 96-3659B
10. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110:847-854
11. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and antiinflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol. 2002;109:68-74
12. Price DB, Hernandez D, Magyar P, et al. Randomized controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-216
13. Busse W, Raphael GD, Galant S, et al. Low dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma. J Allergy Clin Immunol. 2001;107:461-468
14. Kanniess F, Richter K, Böhme S, Jõrres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J. 2002;20:853-858
15. Santanello NC, Davies G, Galant SP, et al. Validation of an asthma symptom diary for interventional studies. Arch Dis Child. 1999;80:414-420
16. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med. 1999;130:487-495
17. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35-46
18. Diette GB, Skinner EA, Markson LE, et al. Consistency of care with national guidelines for children with asthma in managed care. J Pediatr. 2001;138:59-64
19. D'Agostino SR. Non-inferiority trials: advances in concepts and methodology. Stat Med. 2003;22:165-167
20. Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J. 2003;21:123-128
21. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin. 2001;17:96-104
22. LaForce CF, Pearlman DS, Ruff ME, et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann Allergy Asthma Immunol. 2000;85:407-415
23. Katz Y, Lebas FX, Medley HV, Robson R. Fluticasone propionate 50 μg BID versus 100 μg BID in the treatment of children with persistent asthma. Clin Ther. 198;20:424-437
24. Purucker ME, Rosebraugh CJ, Zhou F, Meyer RJ. Inhaled fluticasone propionate by discus in the treatment of asthma. Chest. 2003;124:1584-1593
25. Arets HGM, Kamps AWA, Brackel HJL, Mulder PGH, Vermue NA, van der Ent CK. Children with mild asthma: do they benefit from inhaled corticosteroids? Eur Respir J. 2002;20:1470-1475
26. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001;163:924-929
27. Allen DB, Bronsky EA, LaForce CF, et al. Growth in asthmatic children treated with fluticasone. J Pediatr. 1998;132:472-477
28. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000;106(1). Available at: www.pediatrics.org/cgi/content/full/106/1/e8
29. Randall TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, Van Asperen PP. Safety of the newer inhaled corticosteroids in childhood asthma. Pediatr Drugs. 2003;5:481-504
30. Bisgaard H, Allen D, Milanowski J, Kalev I, Willits L, Davies P. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheeze. Pediatrics. 2004;113(2). Available at: www.pediatrics.org/cgi/content/full/113/2/e87
31. Jonasson G, Carlsen K-H, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy. 2000;55:740-748